|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: LINC01515 |
Gene summary for LINC01515 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | LINC01515 | Gene ID | 101928913 |
| Gene name | long intergenic non-protein coding RNA 1515 | |
| Gene Alias | LINC01515 | |
| Cytomap | 10q21.3 | |
| Gene Type | ncRNA | GO ID | NA | UniProtAcc | NA |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 101928913 | LINC01515 | HTA11_3410_2000001011 | Human | Colorectum | AD | 2.43e-17 | -6.58e-01 | 0.0155 |
| 101928913 | LINC01515 | HTA11_1938_2000001011 | Human | Colorectum | AD | 4.12e-05 | -5.90e-01 | -0.0811 |
| 101928913 | LINC01515 | HTA11_3361_2000001011 | Human | Colorectum | AD | 1.11e-03 | -4.67e-01 | -0.1207 |
| 101928913 | LINC01515 | HTA11_696_2000001011 | Human | Colorectum | AD | 8.33e-09 | -4.67e-01 | -0.1464 |
| 101928913 | LINC01515 | HTA11_5212_2000001011 | Human | Colorectum | AD | 8.26e-04 | -7.01e-01 | -0.2061 |
| 101928913 | LINC01515 | HTA11_866_3004761011 | Human | Colorectum | AD | 1.65e-06 | -4.93e-01 | 0.096 |
| 101928913 | LINC01515 | HTA11_7696_3000711011 | Human | Colorectum | AD | 2.28e-09 | -5.07e-01 | 0.0674 |
| 101928913 | LINC01515 | HTA11_6818_2000001011 | Human | Colorectum | AD | 2.27e-02 | -5.75e-01 | 0.0112 |
| 101928913 | LINC01515 | HTA11_99999971662_82457 | Human | Colorectum | MSS | 3.14e-10 | -4.83e-01 | 0.3859 |
| 101928913 | LINC01515 | HTA11_99999974143_84620 | Human | Colorectum | MSS | 8.45e-13 | -4.83e-01 | 0.3005 |
| 101928913 | LINC01515 | A001-C-207 | Human | Colorectum | FAP | 2.08e-04 | -3.21e-01 | 0.1278 |
| 101928913 | LINC01515 | A015-C-203 | Human | Colorectum | FAP | 7.76e-31 | -6.36e-01 | -0.1294 |
| 101928913 | LINC01515 | A015-C-204 | Human | Colorectum | FAP | 5.22e-12 | -4.73e-01 | -0.0228 |
| 101928913 | LINC01515 | A014-C-040 | Human | Colorectum | FAP | 1.36e-06 | -5.04e-01 | -0.1184 |
| 101928913 | LINC01515 | A002-C-201 | Human | Colorectum | FAP | 5.81e-20 | -5.66e-01 | 0.0324 |
| 101928913 | LINC01515 | A001-C-119 | Human | Colorectum | FAP | 3.99e-12 | -5.56e-01 | -0.1557 |
| 101928913 | LINC01515 | A001-C-108 | Human | Colorectum | FAP | 2.13e-11 | -2.46e-01 | -0.0272 |
| 101928913 | LINC01515 | A002-C-205 | Human | Colorectum | FAP | 2.41e-21 | -5.30e-01 | -0.1236 |
| 101928913 | LINC01515 | A001-C-104 | Human | Colorectum | FAP | 4.08e-06 | -3.52e-01 | 0.0184 |
| 101928913 | LINC01515 | A015-C-005 | Human | Colorectum | FAP | 4.36e-16 | -6.01e-01 | -0.0336 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |